The General Counsel of MRNA, Lori M. Henderson has gone ahead and sold close to 6000 shares of the stock of the company. The entire transaction took place on the 18th of March, with an average price of $144.39.
The Quarterly Estimate of MRNA
The stocks of MRNA traded on Friday, where it reached a sum of $143.74. The market cap of the firm is $57.57 billion, with a PE ratio of around -88.73, and a 0.53 PEG ratio. The year low of the company is $24.36 with a year high of around $189.26. The moving average price of the company over fifty days is $158.90, while the moving average price of the company over 200 days is $113.06. The current ratio for the company is 2.43, while the company enjoys a 0.04 debt-to-equity ratio.
The shares of MRNA previously posted their quarterly data on the 25th of February. The EPS reported by the company over the period was $0.69, which missed out on the consensus estimate of around $0.25. The net margin of the company has been a negative 242.73%, while the return on equity has been at a negative 28.11%. The revenue of the company for the quarter was $570.80 million, which comprehensively beat the consensus estimate of about $279.4 million.
There have been quite a few research equities that have commented on the stocks of MRNA. Morgan Stanley has already decreased the price target of the company from $215 to $201, with a rating of equal weight in a 4th March research report. Chardan Capital has also increased the price target of the company from $107 to $182, with a rating of buy.
